Cancer

Disclaimer

This document provides a general overview of cancer principles for educational purposes and is not intended to replace the clinical judgment of a healthcare professional. Cancer is a highly diverse group of diseases, and management strategies are specific to the type, stage, and individual patient characteristics. Treatment decisions must always be made in consultation with a qualified oncology team, considering the latest evidence, patient preferences, and local guidelines. Dosages and specific treatment protocols mentioned are examples and subject to change based on evolving research and individual patient factors.

Overview

• Definition: Cancer is a broad term for a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. These cells, called malignant cells, have the ability to invade surrounding tissues (local invasion) and spread to distant sites in the body (metastasis) through the bloodstream or lymphatic system.
• Epidemiology:
  • Global Burden: Cancer is a leading cause of death worldwide, responsible for nearly 10 million deaths in 2020. It is the second leading cause of death globally, after cardiovascular disease.
  • Incidence: Approximately 1 in 2 men and 1 in 3 women will be diagnosed with cancer in their lifetime. Incidence rates vary significantly by geographic region, socioeconomic status, and ethnic group, reflecting differences in risk factor exposure and screening practices.
  • Common Cancers: Globally, the most common cancers (in terms of new cases in 2020) were breast, lung, colorectal, prostate, and stomach cancers.
  • Mortality: Lung cancer remains the leading cause of cancer death worldwide, followed by colorectal, liver, stomach, and breast cancers.
• Classification: Cancers are broadly classified based on the cell type from which they originate:
  • Carcinoma: Cancers that arise from epithelial cells (cells that line organs and body surfaces). This is the most common type, accounting for 80-90% of all cancers (e.g., breast, lung, colon, prostate, skin cancers).
    • Adenocarcinoma: Cancers that form in glandular tissue (e.g., breast, colon, prostate, lung adenocarcinoma).
    • Squamous Cell Carcinoma: Cancers that form in squamous cells (flat cells that line many organs, e.g., skin, esophagus, lung squamous cell carcinoma).
  • Sarcoma: Cancers that arise from connective tissues (bone, cartilage, fat, muscle, blood vessels, or other mesenchymal tissues) (e.g., osteosarcoma, liposarcoma, rhabdomyosarcoma).
  • Leukemia: Cancers of the blood-forming tissues in the bone marrow, resulting in the overproduction of abnormal white blood cells (e.g., acute myeloid leukemia, chronic lymphocytic leukemia).
  • Lymphoma: Cancers that originate in the lymphocytes (a type of white blood cell) and typically affect the lymphatic system (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma).
  • Myeloma: Cancer of plasma cells, a type of white blood cell, found in the bone marrow (e.g., multiple myeloma).
  • Brain and Spinal Cord Tumors: Cancers that arise in the brain or spinal cord, categorized by the type of cell from which they originate (e.g., glioma, meningioma).
  • Germ Cell Tumors: Cancers that begin in the cells that give rise to sperm or eggs, often found in the testes or ovaries, but can also occur in other parts of the body (e.g., teratoma, seminoma).
  • Blastoma: Cancers that arise from immature "blast" cells (e.g., neuroblastoma, retinoblastoma, nephroblastoma/Wilms tumor), most common in children.

Pathophysiology

• Mechanism: Cancer development (carcinogenesis) is a multi-step process involving accumulation of genetic and epigenetic alterations in somatic cells, leading to uncontrolled proliferation, evasion of apoptosis, sustained angiogenesis, tissue invasion, and metastasis. Key hallmarks include:
  • Sustaining Proliferative Signaling: Cancer cells acquire the ability to grow and divide without external signals.
  • Evading Growth Suppressors: Inactivation of tumor suppressor genes (e.g., TP53, Rb) removes brakes on cell division.
  • Resisting Cell Death: Cancer cells bypass programmed cell death (apoptosis).
  • Enabling Replicative Immortality: Cancer cells can divide indefinitely, often through activation of telomerase.
  • Inducing Angiogenesis: Formation of new blood vessels to supply nutrients and oxygen to the tumor.
  • Activating Invasion and Metastasis: Cancer cells acquire mobility and the ability to degrade extracellular matrix, allowing them to spread.
  • Deregulating Cellular Energetics: Cancer cells often rely on aerobic glycolysis (Warburg effect).
  • Avoiding Immune Destruction: Cancer cells develop mechanisms to evade recognition and elimination by the immune system.
  • Tumor-Promoting Inflammation: Chronic inflammation can create a microenvironment conducive to tumor growth and progression.
  • Genome Instability and Mutation: Increased mutation rates accelerate the acquisition of cancer hallmarks.
• Risk Factors:
  • Modifiable:
    • Lifestyle: Tobacco use (single largest preventable cause), excessive alcohol consumption, unhealthy diet (high red/processed meat, low fruits/vegetables), physical inactivity, obesity.
    • Infections: Certain viruses (e.g., HPV – cervical, oropharyngeal; HBV/HCV – liver; EBV – nasopharyngeal, lymphoma; HIV – Kaposi's sarcoma, lymphoma) and bacteria (e.g., Helicobacter pylori – gastric).
    • Environmental/Occupational Exposures: Ionizing radiation (medical, occupational, nuclear), ultraviolet (UV) radiation (sunlight, tanning beds), exposure to carcinogens (e.g., asbestos, benzene, arsenic, formaldehyde, diesel exhaust, certain pesticides).
    • Medical Treatments: Immunosuppressive drugs, certain chemotherapy agents, radiation therapy for previous cancers.
  • Non-modifiable:
    • Age: The strongest risk factor; risk increases significantly with age due to accumulation of somatic mutations and reduced immune surveillance.
    • Genetics/Heredity: Inherited genetic mutations (e.g., BRCA1/2 for breast/ovarian, Lynch syndrome for colorectal/endometrial) account for 5-10% of cancers.
    • Family History: Even without a known genetic mutation, a strong family history may indicate shared genetic predispositions or environmental exposures.
    • Race/Ethnicity: Disparities exist due to genetic predispositions, socioeconomic factors, and healthcare access.
    • Chronic Inflammation: Conditions like inflammatory bowel disease (colorectal cancer) or chronic pancreatitis (pancreatic cancer).
• Protective Factors:
  • Lifestyle:
    • Healthy Diet: Rich in fruits, vegetables, whole grains, and lean proteins; limited processed foods, red meat, and sugary drinks.
    • Regular Physical Activity: Aim for at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic activity per week, plus strength training.
    • Maintaining a Healthy Weight: Avoid obesity.
    • Smoking Cessation: Eliminates the largest preventable risk factor.
    • Moderate Alcohol Consumption: Limiting or avoiding alcohol.
    • Sun Protection: Limiting UV exposure, using sunscreen, protective clothing.
  • Vaccinations:
    • HPV Vaccine: Prevents HPV-related cancers (cervical, anal, oropharyngeal, vaginal, vulvar, penile).
    • HBV Vaccine: Prevents Hepatitis B virus infection, reducing risk of hepatocellular carcinoma.
  • Chemoprevention: Use of medications to reduce cancer risk in high-risk individuals (e.g., tamoxifen/raloxifene for breast cancer in high-risk women, aspirin for colorectal cancer in certain populations).
  • Screening: Regular screening for early detection (secondary prevention) can significantly reduce mortality for some cancers (see Prevention section).

Clinical Presentation

Cancer symptoms are highly variable depending on the type, location, size, and spread of the tumor. Many early cancers are asymptomatic.

Signs and Symptoms

General warning signs often prompted by the acronym CAUTION: - Change in bowel or bladder habits - A sore that does not heal - Unusual bleeding or discharge - Thickening or lump in the breast or elsewhere - Indigestion or difficulty swallowing - Obvious change in a wart or mole - Nagging cough or hoarseness

• Cardinal Features:
  • Unexplained weight loss: Significant, unintentional loss (e.g., >10% of body weight over 6 months) is a red flag.
  • Fatigue: Persistent, profound fatigue unrelated to activity or rest.
  • Fever: Unexplained, persistent fever, often intermittent, especially at night.
  • Pain: New, persistent, or worsening pain that is not relieved by common measures. Localized pain may indicate tumor involvement (e.g., bone pain in metastatic disease).
  • Lumps or Swellings: Palpable masses, especially if new, rapidly growing, hard, fixed, or painless (e.g., breast lump, swollen lymph nodes).
  • Changes in Bowel/Bladder Habits: Persistent diarrhea, constipation, narrowed stool, blood in stool, painful urination, frequency, or urgency.
  • Unusual Bleeding or Discharge: Blood in stool, urine, vaginal bleeding after menopause or between periods, nipple discharge, coughing up blood.
• Early Signs: Often subtle and non-specific, leading to delayed diagnosis.
  • Mild dyspepsia (gastric/esophageal cancer)
  • Persistent cough (lung cancer)
  • Fatigue (leukemia, lymphoma, many solid tumors)
  • Skin changes (new or changing moles for melanoma)
  • Breast changes (new lump, skin dimpling, nipple inversion)
• Advanced Signs: Reflect significant tumor burden or metastasis.
  • Cachexia: Severe wasting syndrome with weight loss, muscle atrophy, fatigue, weakness, and loss of appetite.
  • Organ Dysfunction:
    • Jaundice (liver metastases, pancreatic cancer)
    • Shortness of breath (pleural effusions, lung involvement)
    • Neurological deficits (brain metastases, spinal cord compression)
    • Bone fractures (bone metastases)
    • Bowel obstruction (abdominal tumors)
  • Significant Pain: Often requiring opioid analgesia.
  • Swelling/Lymphedema: Due to lymphatic obstruction or venous compression.
• Atypical Presentations:
  • Paraneoplastic Syndromes: Remote effects of cancer not due to direct invasion, obstruction, or metastasis. Caused by substances (hormones, cytokines, antibodies) secreted by the tumor or by an immune response against the tumor.
    • Endocrine: SIADH (small cell lung cancer), hypercalcemia of malignancy (squamous cell lung, kidney, breast, multiple myeloma), Cushing's syndrome (small cell lung cancer, adrenal).
    • Neurological: Lambert-Eaton myasthenic syndrome (small cell lung cancer), paraneoplastic cerebellar degeneration, limbic encephalitis.
    • Hematological: Anemia (common), polycythemia (renal cell carcinoma), Trousseau's syndrome (migratory thrombophlebitis, often associated with pancreatic, lung, GI cancers).
    • Dermatological: Acanthosis nigricans, dermatomyositis, Leser-Trélat sign.
  • Constitutional Symptoms Alone: Fever of unknown origin, persistent fatigue without other localized signs.

Physical Examination

The physical exam should be comprehensive, tailored to the patient's symptoms, and include attention to areas common for cancer development.

• Inspection:
  • General Appearance: Cachexia, pallor, jaundice, skin lesions (rashes, nodules, pigmentation changes), telangiectasias.
  • Skin: Moles (size, shape, color, symmetry, evolving/changing), unhealing sores, unusual bleeding.
  • Lymph Nodes: Visible swelling in cervical, supraclavicular, axillary, inguinal regions.
  • Breast: Asymmetry, dimpling, nipple changes (inversion, discharge), redness, orange peel appearance (peau d'orange).
  • Abdomen: Distension, asymmetry, visible masses.
• Palpation:
  • Lymph Nodes: Assess size, consistency (firm, rubbery, stony hard), mobility (fixed vs. mobile), tenderness. Supraclavicular nodes (Virchow's node) are highly suspicious for malignancy.
  • Breast: Palpate for lumps (size, shape, consistency, mobility, tenderness, borders), axillary nodes.
  • Abdomen: Palpate for organomegaly (hepatomegaly, splenomegaly), masses, tenderness, ascites.
  • Thyroid: Palpate for nodules, goiter.
  • Rectal/Pelvic:
    • Digital Rectal Exam (DRE): Prostate size, consistency, nodules, tenderness; rectal masses.
    • Pelvic Exam: Uterine size, adnexal masses, cervical abnormalities.
  • Testicular: Palpate for masses, asymmetry, tenderness.
  • Bone/Joints: Tenderness, swelling, deformity.
• Special Tests:
  • Neurological Exam: For suspected brain/spinal cord involvement (e.g., cranial nerve palsies, motor/sensory deficits, reflexes, gait).
  • Ophthalmoscopy: For suspected ocular tumors (e.g., retinoblastoma) or signs of increased intracranial pressure.

Diagnostic Approach

The diagnostic approach aims to confirm the presence of cancer, determine its type and extent (staging), and identify molecular characteristics relevant for treatment.

History Taking

• Key Questions:
  • Symptom Onset and Duration: When did symptoms start? Have they changed?
  • Constitutional Symptoms: Weight loss, fever, night sweats, fatigue (B symptoms for lymphoma/leukemia).
  • Specific Symptoms: Detailed inquiry about the "CAUTION" signs, or system-specific symptoms (e.g., dysphagia for esophageal cancer, hemoptysis for lung cancer, change in bowel habits for colorectal cancer).
  • Risk Factor Assessment: Smoking history (type, duration, packs/year), alcohol use, occupational exposures, sun exposure, diet, physical activity.
  • Family History: Any first-degree relatives with cancer? At what age were they diagnosed? What type of cancer? Any known genetic syndromes?
  • Past Medical History: Previous cancers, chronic inflammatory conditions, immunosuppression, previous radiation therapy.
  • Medications: Including over-the-counter and supplements.
  • Social History: Living situation, support system, impact of symptoms on daily life.
• Red Flags:
  • Unexplained, persistent symptoms: Especially if progressive or refractory to initial management.
  • Rapid, unintentional weight loss: >10% of body weight in 6 months without obvious cause.
  • New-onset focal neurological deficits.
  • Persistent blood in stool, urine, or cough.
  • New, persistent lump or swelling, especially if hard or fixed.
  • Persistent hoarseness or dysphagia.
  • Unexplained bone pain, especially if worsening at night.
  • Recurrent fevers or night sweats without infection.

Laboratory Tests

• First-Line: Used for initial assessment, general health status, and to identify potential complications or contribute to suspicion.
  • Complete Blood Count (CBC) with Differential: Anemia (chronic disease, bleeding, marrow involvement), leukocytosis/leukopenia (leukemia, bone marrow suppression), thrombocytopenia/thrombocytosis.
  • Basic Metabolic Panel (BMP) / Liver Function Tests (LFTs) / Renal Function Tests: Assess kidney and liver function, electrolytes (e.g., hypercalcemia of malignancy), albumin.
  • Inflammatory Markers: ESR, CRP (non-specific, but may be elevated in malignancy).
  • Urinalysis: Hematuria (bladder, kidney cancer), proteinuria.
  • Stool Occult Blood Test (FOBT/FIT): Screening for colorectal cancer.
• Confirmatory: Biopsy and histopathological examination are the gold standard for cancer diagnosis.
  • Tissue Biopsy:
    • Incisional/Excisional Biopsy: Removal of part or all of a suspicious mass.
    • Core Needle Biopsy: Using a needle to obtain tissue cylinders from a mass.
    • Fine Needle Aspiration (FNA): Aspirating cells from a mass, less definitive for architectural diagnosis but useful for rapid assessment.
    • Endoscopic Biopsy: Via bronchoscopy, colonoscopy, gastroscopy, cystoscopy.
    • Bone Marrow Biopsy: For hematological malignancies.
    • Liquid Biopsy: Analysis of circulating tumor DNA (ctDNA) from blood, increasingly used for mutation detection, monitoring, and resistance, but not yet primary diagnosis.
  • Pathology Review: Microscopic examination of tissue by a pathologist, often including immunohistochemistry (IHC) and molecular/genetic testing (e.g., FISH, PCR, NGS) to determine specific cancer type, grade, and molecular profile (e.g., EGFR mutation, ALK rearrangement, PD-L1 expression) for targeted therapies.
  • Cytogenetics/FISH/Molecular Studies: For leukemias, lymphomas, and some solid tumors (e.g., HER2 amplification in breast cancer).
• Monitoring: Used during and after treatment to assess response, detect recurrence, and monitor for side effects.
  • Tumor Markers: Glycoproteins or other substances produced by cancer cells or by the body in response to cancer. Not used for screening in the general population due to low specificity and sensitivity, but useful for monitoring in diagnosed cancer cases.
    • CEA (Carcinoembryonic Antigen): Colorectal, lung, breast, gastric, pancreatic.
    • CA 19-9 (Carbohydrate Antigen 19-9): Pancreatic, biliary, gastric, colorectal.
    • CA 125 (Cancer Antigen 125): Ovarian, sometimes others (endometrial, lung).
    • PSA (Prostate-Specific Antigen): Prostate cancer (screening, diagnosis, and monitoring).
    • AFP (Alpha-Fetoprotein): Hepatocellular carcinoma, germ cell tumors.
    • hCG (Human Chorionic Gonadotropin): Germ cell tumors, gestational trophoblastic disease.
    • LDH (Lactate Dehydrogenase): Non-specific, but elevated in many cancers, especially lymphoma, melanoma, germ cell tumors.
    • Beta-2 Microglobulin: Multiple myeloma, lymphoma, chronic lymphocytic leukemia.
  • CBC, LFTs, Renal function: Regularly throughout treatment to monitor for toxicity.

Imaging

Imaging plays a crucial role in initial detection, staging (determining the extent of disease), assessing treatment response, and surveillance for recurrence.

• Recommended (Standard Staging):
  • Computed Tomography (CT) Scan: Provides detailed cross-sectional images. Essential for staging most solid tumors (chest, abdomen, pelvis CT) to detect primary tumor size, local invasion, lymph node involvement, and distant metastases (lung, liver, bone).
  • Chest X-ray (CXR): May be a first-line screen for lung abnormalities, but CT is more sensitive.
  • Ultrasound (US): Useful for initial evaluation of masses in superficial organs (breast, thyroid, testes), pelvic organs (ovaries, uterus), and guiding biopsies. Often used to differentiate cystic vs. solid lesions.
  • Magnetic Resonance Imaging (MRI): Superior for soft tissue contrast.
    • Brain/Spine MRI: For suspected CNS tumors or metastases.
    • Pelvic MRI: For gynecological (cervical, ovarian, uterine) and prostate cancers.
    • Musculoskeletal MRI: For bone and soft tissue sarcomas.
• Advanced (Specialized Imaging): Used when specific information is needed or for particular cancer types.
  • Positron Emission Tomography (PET-CT) Scan: Combines PET (metabolic activity, often using FDG, a glucose analog) with CT (anatomical localization). Highly sensitive for detecting metabolically active tumors and metastases, particularly useful for staging and restaging many cancers (e.g., lung, lymphoma, melanoma, colorectal, head & neck). Can differentiate benign from malignant lesions and assess treatment response.
  • Bone Scan (Technetium-99m bone scintigraphy): Identifies areas of increased bone turnover, indicative of bone metastases. Highly sensitive but not specific; follow-up X-rays or MRI may be needed to confirm.
  • Endoscopic Ultrasound (EUS): For cancers of the GI tract, pancreas, bile duct; provides detailed imaging of tumor depth and regional lymph nodes, and allows for FNA biopsy.
  • Mammography: Primary screening tool for breast cancer.
  • DEXA Scan: Baseline and follow-up for bone density in patients at risk of bone loss (e.g., on certain hormonal therapies).

Management

Cancer management is highly individualized, multi-modal, and requires a multidisciplinary team approach (oncologists, surgeons, radiation oncologists, pathologists, radiologists, nurses, palliative care specialists, social workers, dietitians, psychologists). The choice of treatment depends on cancer type, stage, molecular characteristics, patient performance status, comorbidities, and preferences.

Acute Management (Oncologic Emergencies)

These are life-threatening conditions caused by cancer or its treatment, requiring immediate recognition and intervention.

• Immediate Interventions:
  • Airway/Breathing/Circulation (ABC) Management: Stabilize vital signs.
  • Rapid Assessment: Identify the oncologic emergency.
  • Symptom Control: Aggressive pain and symptom management.
• Stabilization:
  • Superior Vena Cava (SVC) Syndrome: Caused by compression of the SVC, often by lung cancer or lymphoma. Symptoms: facial/upper extremity swelling, dyspnea, plethora, dilated neck veins.
    • Management: Elevate head, supplemental oxygen, diuretics (furosemide 20-40 mg IV), corticosteroids (dexamethasone 4-8 mg IV Q6h if suspect steroid-sensitive tumor or cerebral edema), urgent radiation therapy, stenting in severe cases.
  • Spinal Cord Compression (SCC): Often due to epidural metastases (breast, lung, prostate, kidney, myeloma). Symptoms: new or worsening back pain (often worse when lying down), weakness, sensory deficits, bladder/bowel dysfunction.
    • Management: High-dose corticosteroids (dexamethasone 10-20 mg IV bolus, then 4 mg IV Q6h), urgent MRI, emergent radiation therapy, neurosurgical consultation for decompression/stabilization.
  • Hypercalcemia of Malignancy: Common metabolic emergency, often from PTHrP secretion (squamous cell lung, renal cell) or bone metastases (myeloma, breast). Symptoms: lethargy, confusion, constipation, polyuria, nausea, vomiting. Serum calcium >12 mg/dL is severe.
    • Management: Aggressive IV hydration (Normal Saline 200-500 mL/hr), loop diuretics (furosemide 20-40 mg IV after rehydration), bisphosphonates (zolendronic acid 4 mg IV over 15 min or pamidronate 60-90 mg IV over 2-4 hr), calcitonin (4 units/kg SC/IM Q12h for rapid but short-lived effect), dialysis in severe refractory cases.
  • Neutropenic Fever: Fever (single oral temp ≥38.3°C or ≥38.0°C sustained for ≥1 hr) in a neutropenic patient (ANC <500 cells/µL or expected to drop <500 in 48 hr). Often due to bacterial infection.
    • Management: Prompt empiric broad-spectrum IV antibiotics (e.g., cefepime 2g IV Q8h, meropenem 1g IV Q8h, piperacillin-tazobactam 4.5g IV Q6h) within 1 hour of presentation, blood cultures, consider antifungals if persistent fever after 4-7 days on broad-spectrum antibiotics.
  • Tumor Lysis Syndrome (TLS): Rapid breakdown of tumor cells, releasing intracellular contents (potassium, phosphate, nucleic acids) into circulation. Common with highly chemosensitive, bulky tumors (lymphoma, leukemia). Symptoms: hyperkalemia (cardiac arrhythmias), hyperphosphatemia (renal failure, hypocalcemia), hyperuricemia (uric acid nephropathy).
    • Management: Aggressive IV hydration (2.5-3 L/m²/day), allopurinol (300 mg daily) or rasburicase (0.2 mg/kg IV once for rapid uric acid reduction) for hyperuricemia, monitor electrolytes, correct abnormalities, consider dialysis for severe refractory cases.
• Emergency: Immediate consultation with oncology/relevant specialists.

Chronic Management

A long-term strategy involving definitive treatment, supportive care, and surveillance.

• Pharmacological: Systemic therapies target cancer cells throughout the body.
  • Chemotherapy: Cytotoxic drugs that kill rapidly dividing cells (both cancerous and healthy). Administered intravenously or orally, often in cycles. Examples: cisplatin, doxorubicin, 5-fluorouracil, cyclophosphamide. Side effects are common and varied (myelosuppression, nausea, hair loss, fatigue, neuropathy).
  • Targeted Therapy: Drugs designed to specifically interfere with molecular pathways crucial for cancer growth and survival, often based on the tumor's genetic profile. Generally less toxic than traditional chemotherapy. Examples:
    • Tyrosine Kinase Inhibitors (TKIs): Imatinib (for CML, GIST), erlotinib/osimertinib (for EGFR-mutated lung cancer), trastuzumab (HER2-positive breast cancer).
    • PARP Inhibitors: Olaparib (for BRCA-mutated ovarian/breast cancer).
  • Immunotherapy: Harnesses the body's immune system to fight cancer.
    • Immune Checkpoint Inhibitors (ICIs): Block proteins (e.g., PD-1, PD-L1, CTLA-4) that normally put brakes on the immune system, allowing T cells to recognize and kill cancer cells. Examples: pembrolizumab, nivolumab, ipilimumab. Effective in melanoma, lung, renal, bladder, MSI-high colorectal cancers.
    • CAR T-Cell Therapy: Genetically engineering a patient's T cells to target and kill cancer cells, primarily for hematological malignancies (e.g., refractory lymphoma, leukemia).
  • Hormonal Therapy: Used for hormone-sensitive cancers (e.g., breast, prostate). Blocks hormone production or action.
    • Anti-estrogens: Tamoxifen, aromatase inhibitors (anastrozole, letrozole) for breast cancer.
    • Anti-androgens: Leuprolide, bicalutamide for prostate cancer.
• Non-pharmacological:
  • Surgery: Removal of the primary tumor and sometimes regional lymph nodes. Curative for many early-stage solid tumors. Can also be palliative (e.g., debulking, stenting).
  • Radiation Therapy: Uses high-energy rays (X-rays, gamma rays, protons) to kill cancer cells or shrink tumors. Can be external beam or internal (brachytherapy). Used curatively (e.g., prostate, head & neck), adjuvantly (after surgery), neoadjuvantly (before surgery), or palliatively (pain relief, bleeding control).
  • Palliative Care: Focuses on providing relief from the symptoms and stress of a serious illness. Improves quality of life for both the patient and the family. Should be integrated early in the disease course, alongside curative treatments.
  • Nutritional Support: Manages cancer-related cachexia, malnutrition, and treatment side effects (e.g., nausea, mucositis).
  • Psychosocial Support: Addresses emotional distress, anxiety, depression, body image issues. Includes counseling, support groups, and psychiatric referrals.
  • Rehabilitation: Physical, occupational, and speech therapy to restore function lost due to cancer or treatment.
• Monitoring:
  • Regular Follow-up Appointments: Clinical examination, symptom review.
  • Imaging: Surveillance scans (CT, MRI, PET) at prescribed intervals depending on cancer type and stage.
  • Laboratory Tests: Tumor markers (if applicable), CBC, LFTs, renal function to monitor for recurrence and long-term treatment effects.
  • Screening for Secondary Malignancies: For patients treated with certain therapies (e.g., breast cancer survivors screened for secondary leukemias).

Treatment Algorithms

General approach, highly specific by cancer type and stage.

• First-Line: Standard of care treatment for a specific cancer at a specific stage, based on highest level of evidence (randomized controlled trials). Often involves surgery, radiation, or systemic therapy (chemo, targeted, immuno), or a combination.
  • Early-Stage, Localized Solid Tumors: Often curative with surgery alone (e.g., T1 breast cancer, early colon cancer) or surgery + adjuvant therapy (chemo, radiation, hormonal) to prevent recurrence.
  • Locally Advanced Solid Tumors: May involve neoadjuvant therapy (chemo/radiation before surgery to shrink tumor), surgery, followed by adjuvant therapy. Definitive chemoradiation may be an option for non-surgical candidates or certain tumor types (e.g., head and neck, esophageal).
  • Hematological Malignancies: Often treated with systemic therapy (chemotherapy, targeted therapy, immunotherapy, stem cell transplant) depending on type and risk stratification.
• Second-Line: Used when first-line treatment fails (progression) or is intolerable. May involve different chemotherapy agents, alternative targeted therapies, or different immunotherapy agents. Selection is often guided by molecular profiling of the progressing tumor.
• Refractory Cases: When cancer progresses despite multiple lines of standard therapy.
  • Palliative Care: Increased focus on symptom management and quality of life.
  • Clinical Trials: Patients may be eligible for experimental treatments in clinical trials, offering access to novel agents.
  • Best Supportive Care: When further active anti-cancer treatment is not beneficial or desired.

Complications

Complications can arise from the cancer itself (due to tumor burden, invasion, metastasis) or from its treatment.

• Common:
  • Fatigue: Most common and debilitating symptom of cancer and its treatment.
  • Pain: Due to tumor invasion, nerve compression, bone metastases, or treatment-related (e.g., neuropathy from chemotherapy, post-surgical pain).
  • Nausea and Vomiting: Common with chemotherapy and radiation, can also be tumor-related (e.g., bowel obstruction).
  • Anemia: From chronic disease, bleeding, bone marrow suppression by tumor or chemotherapy.
  • Infection: Due to myelosuppression (neutropenia) from chemotherapy or tumor involvement of immune organs.
  • Hair Loss (Alopecia): Common with many chemotherapies.
  • Mucositis: Inflammation and ulceration of mucous membranes, especially oral.
  • Peripheral Neuropathy: Common with certain chemotherapies (e.g., taxanes, platinum agents).
  • Lymphedema: Swelling due to impaired lymphatic drainage, often after lymph node dissection or radiation.
• Serious:
  • Oncologic Emergencies: (See Acute Management section: SVC syndrome, SCC, hypercalcemia, neutropenic fever, TLS).
  • Thromboembolism (VTE): Cancer patients are at significantly increased risk of DVT/PE due to pro-coagulant state (Trousseau's syndrome), immobility, and treatment.
  • Organ Failure: Liver failure (extensive metastases), renal failure (TLS, obstructive uropathy, chemotherapy-induced), cardiac dysfunction (anthracycline cardiotoxicity).
  • Bowel Obstruction/Perforation: Due to intraluminal tumor, extrinsic compression, or treatment-related adhesions.
  • Hemorrhage: Due to tumor erosion into vessels, coagulopathy, or thrombocytopenia.
  • Treatment-Related Toxicities:
    • Cardiotoxicity: Anthracyclines (doxorubicin), trastuzumab.
    • Pulmonary Toxicity: Bleomycin, radiation pneumonitis, immune checkpoint inhibitor pneumonitis.
    • Nephrotoxicity: Cisplatin, ifosfamide.
    • Immunotherapy-Related Adverse Events (irAEs): Autoimmune-like toxicities affecting various organs (colitis, hepatitis, endocrinopathies, pneumonitis, dermatitis).
• Long-term:
  • Secondary Malignancies: Increased risk of new cancers after successful treatment for a primary cancer, especially after radiation or certain chemotherapies (e.g., AML after alkylating agents).
  • Organ Damage: Chronic cardiac, pulmonary, renal, neurological, or endocrine dysfunction due to radiation or chemotherapy.
  • Cognitive Dysfunction ("Chemo Brain"): Persistent issues with memory, attention, and executive function.
  • Infertility: Common after chemotherapy or radiation, especially in younger patients.
  • Psychological Distress: Anxiety, depression, PTSD, fear of recurrence.
  • Pain Syndromes: Chronic neuropathic pain, post-mastectomy pain syndrome.
  • Sexual Dysfunction: Due to hormonal changes, nerve damage, or psychological factors.
  • Osteoporosis: Due to hormonal therapies or long-term steroid use.

Prognosis

Prognosis in cancer is highly variable and depends on numerous factors.

• Factors Affecting Outcome:
  • Cancer Type: Some cancers are inherently more aggressive (e.g., pancreatic adenocarcinoma) than others (e.g., basal cell carcinoma).
  • Stage at Diagnosis: The most critical prognostic factor.
    • Localized: Cancer confined to the primary site.
    • Regional: Cancer has spread to nearby lymph nodes or tissues.
    • Distant: Cancer has metastasized to distant organs.
  • Histological Grade: How abnormal the cancer cells look under a microscope (differentiation). Lower grade (well-differentiated) usually means better prognosis than higher grade (poorly differentiated or anaplastic).
  • Molecular and Genetic Markers: Presence of specific mutations (e.g., EGFR, ALK, BRAF, KRAS), gene amplifications (e.g., HER2), or protein expressions (e.g., PD-L1, hormone receptors) can predict response to targeted therapy/immunotherapy and influence prognosis.
  • Patient Performance Status (PS): A measure of a patient's general well-being and ability to perform daily activities (e.g., ECOG or Karnofsky scores). Better PS correlates with better tolerance to treatment and better outcomes.
  • Comorbidities: Pre-existing medical conditions can impact treatment tolerability and overall survival.
  • Age: Generally, younger patients may tolerate aggressive therapies better, but older patients may have slower-growing tumors. Extremely young or old age can be risk factors.
  • Treatment Response: How well the tumor responds to initial therapy.
  • Tumor Burden/Bulk: Larger tumors or extensive metastatic disease generally portend worse prognosis.
• Survival:
  • 5-Year Survival Rates: A commonly cited metric, indicating the percentage of people who are alive 5 years after diagnosis. These rates are highly cancer-specific and stage-dependent (e.g., >90% for early breast/prostate cancer, <10% for metastatic pancreatic cancer).
  • Overall Survival (OS): The length of time from diagnosis or start of treatment that patients are still alive.
  • Progression-Free Survival (PFS): The length of time during and after treatment that the disease does not grow or spread.
• Quality of Life: Increasingly recognized as a crucial outcome measure alongside survival. Focuses on physical, emotional, social, and functional well-being. Survivorship care aims to optimize quality of life after treatment completion.

Prevention

Prevention strategies are categorized into primary, secondary, and tertiary.

• Primary Prevention: Aims to prevent cancer from ever occurring by reducing exposure to risk factors and promoting protective factors.

  • Lifestyle Modifications:
    • Tobacco Cessation: Avoid all forms of tobacco. Significant reduction in risk of lung, head & neck, bladder, pancreatic, and many other cancers.
    • Healthy Diet: Emphasize fruits, vegetables, whole grains; limit red and processed meats, sugary drinks, and highly processed foods.
    • Regular Physical Activity: Aim for at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic activity per week.
    • Weight Management: Maintain a healthy body mass index (BMI 18.5-24.9 kg/m²).
    • Limit Alcohol Consumption: If consumed, limit to 1 drink/day for women and 2 drinks/day for men.
    • Sun Protection: Seek shade, wear protective clothing, use broad-spectrum sunscreen (SPF 30+) when outdoors. Avoid tanning beds.
  • Vaccinations:
    • Human Papillomavirus (HPV) Vaccine: Recommended for adolescents (ages 9-26, ideally before sexual activity) to prevent HPV-related cancers (cervical, anal, oropharyngeal, etc.). Catch-up vaccination up to age 45 may be considered.
    • Hepatitis B Virus (HBV) Vaccine: Recommended for infants and high-risk adults to prevent chronic HBV infection, a major cause of hepatocellular carcinoma.
  • Chemoprevention: Use of medications to reduce cancer risk in high-risk individuals.
    • Tamoxifen or Raloxifene: For women at high risk of breast cancer.
    • Aspirin: May reduce colorectal cancer risk in select high-risk individuals (e.g., age 50-69 with high ASCVD risk and low bleeding risk).
  • Avoid Environmental Carcinogens: Minimize exposure to asbestos, radon, industrial chemicals, and air pollution.

• Secondary Prevention: Focuses on early detection and intervention in asymptomatic individuals to prevent disease progression or improve outcomes.

  • Screening Programs:
    • Breast Cancer:
      • Mammography: Annually for women starting at age 40 or 45, continuing until 75 or based on life expectancy (ACS, NCCN guidelines vary slightly).
      • Clinical Breast Exam: Annual or biennial by a healthcare provider.
      • MRI: For high-risk women (e.g., BRCA mutation carriers) in addition to mammography.
    • Cervical Cancer:
      • Pap Test: Every 3 years for women ages 21-65.
      • HPV Testing: Every 5 years for women ages 30-65 (co-testing with Pap, or primary HPV testing).
    • Colorectal Cancer:
      • Colonoscopy: Every 10 years for average-risk individuals starting at age 45 (or 40 if African American or with family history), or more frequently if polyps found or with high-risk conditions.
      • Stool-based tests: Fecal Immunochemical Test (FIT) annually, or Guaiac-based Fecal Occult Blood Test (gFOBT) annually, or multi-target stool DNA test (mt-sDNA) every 1-3 years. Positive tests require follow-up colonoscopy.
    • Lung Cancer:
      • Low-Dose CT (LDCT): Annual screening for high-risk current or former smokers (age 50-80, ≥20 pack-year smoking history, and current smoker or quit within the last 15 years).
    • Prostate Cancer:
      • PSA Blood Test and DRE: Shared decision-making for men ages 50-69 (or starting earlier for high-risk groups, e.g., African American men or those with strong family history). Frequency varies (1-2 years). Not universally recommended due to risk of overdiagnosis and overtreatment.
    • Skin Cancer:
      • Regular self-skin exams and annual professional skin exams, especially for high-risk individuals (e.g., history of melanoma, many atypical nevi, strong family history).
  • Management of Precancerous Lesions: Removal of polyps during colonoscopy, treatment of high-grade cervical dysplasia.

• Tertiary Prevention: Focuses on preventing complications, improving quality of life, and prolonging survival in individuals who have already been diagnosed with cancer.

  • Optimal Treatment: Delivering evidence-based, stage-appropriate anti-cancer therapies.
  • Rehabilitation: Physical, occupational, speech therapy, and psychological counseling to address treatment-related morbidities and restore function.
  • Survivorship Care: Comprehensive follow-up plans to monitor for recurrence, manage long-term side effects, and promote overall health and well-being.
  • Palliative Care: Integrated early to manage symptoms and support quality of life throughout the cancer journey.
  • Health Education: Promoting healthy behaviors to prevent secondary cancers or recurrence.

Special Populations

Pediatric

• Different Tumor Types: Pediatric cancers are distinct from adult cancers. Leukemias, brain tumors, lymphomas, neuroblastoma, Wilms tumor, and sarcomas are most common. Carcinomas are rare.
• Genetics: Higher proportion of inherited genetic predispositions (e.g., Li-Fraumeni syndrome, Down syndrome).
• Treatment: Often tolerate more intensive chemotherapy and radiation. However, high risk of long-term side effects due to developing organs (e.g., growth impairment, organ toxicity, secondary malignancies, neurocognitive deficits).
• Supportive Care: Emphasis on growth, development, psychosocial support for child and family, schooling, and long-term follow-up care.

Geriatric

• Increased Incidence: Cancer incidence increases significantly with age.
• Comorbidities: Elderly patients often have multiple comorbidities, impacting treatment tolerance and selection.
• Frailty: Assessment of frailty is crucial, as chronological age alone is not sufficient. Geriatric assessments can identify vulnerabilities.
• Pharmacokinetics/Pharmacodynamics: Altered drug metabolism and excretion, requiring dose adjustments.
• Cognitive Function: Baseline cognitive assessment important for treatment decisions and patient education.
• Support System: May have limited social support.
• Goals of Care: Shared decision-making is paramount, balancing aggressive treatment with quality of life and avoiding overtreatment or under-treatment. Palliative care integration is key.

Pregnancy

• Diagnosis Challenges: Symptoms can be masked by pregnancy, imaging choice limited (avoid radiation), biopsy may be delayed.
• Fetal Safety: Treatment decisions involve balancing maternal outcome with fetal safety.
• Treatment Modifications:
  • Surgery: Generally safe in all trimesters, with precautions.
  • Chemotherapy: Generally avoided in the first trimester due to teratogenicity. May be given in 2nd/3rd trimesters after organogenesis, but timing to delivery is crucial.
  • Radiation Therapy: Generally contraindicated due to fetal radiation exposure.
  • Targeted/Immunotherapy: Limited data, generally avoided.
• Multidisciplinary Team: Obstetrics, maternal-fetal medicine, oncology, neonatology, and palliative care collaborate closely.
• Considerations: Mode of delivery, timing of delivery, breast vs. formula feeding.

Comorbidities

• Cardiovascular Disease: Pre-existing heart conditions limit cardiotoxic agents (e.g., anthracyclines, trastuzumab). Close monitoring during treatment.
• Renal Impairment: Requires dose adjustments for renally excreted drugs (e.g., cisplatin, carboplatin). Risk of nephrotoxicity from treatment.
• Hepatic Impairment: Requires dose adjustments for hepatically metabolized drugs (e.g., many chemotherapies, targeted therapies).
• Diabetes: Steroids (common in chemotherapy regimens) can exacerbate hyperglycemia. Careful glucose monitoring and management.
• Chronic Lung Disease: Limits pulmonary toxic agents (e.g., bleomycin, radiation).
• Neurological Conditions: Pre-existing neuropathy can worsen with neurotoxic chemotherapy.
• Immunosuppression: Patients are already at higher risk of infection, which is exacerbated by chemotherapy.

Clinical Pearls

• Diagnostic:
  • Always consider malignancy: In patients with unexplained, persistent, or progressive symptoms, especially if new onset in an older individual.
  • Tissue is the issue: Definitive diagnosis of cancer always requires pathological examination of tissue. Imaging alone is rarely sufficient.
  • B symptoms matter: Unexplained fever, drenching night sweats, and significant weight loss should always prompt a thorough malignancy workup.
  • Unexplained lymphadenopathy: Especially if firm, non-tender, persistent, or in supraclavicular region, warrants biopsy.
  • Paraneoplastic syndromes can precede cancer diagnosis: Consider occult malignancy in patients presenting with new-onset neurological, endocrine, or rheumatological symptoms without a clear etiology.
• Treatment:
  • Multidisciplinary approach: Cancer care is complex; involve surgeons, radiation oncologists, medical oncologists, and supportive care early.
  • Shared decision-making: Always discuss treatment options, potential benefits, risks, side effects, and patient preferences.
  • Performance status is critical: It often dictates treatment intensity and tolerability more than chronological age.
  • Early palliative care integration: Improves symptom control, quality of life, and sometimes even survival. Not just for end-of-life.
  • Address symptoms aggressively: Pain, nausea, fatigue, and other symptoms significantly impact quality of life and treatment adherence.
  • Prevent complications: Prophylactic antiemetics, growth factors (G-CSF) for neutropenia, DVT prophylaxis for high-risk patients.
• Pitfalls:
  • Dismissing vague symptoms: Especially in elderly patients, attributing symptoms solely to aging can delay diagnosis.
  • Over-reliance on tumor markers for screening: Most tumor markers lack sufficient sensitivity and specificity for general population screening and can lead to false positives and unnecessary anxiety/workups.
  • Missing oncologic emergencies: Delayed recognition and management of SVC syndrome, spinal cord compression, or hypercalcemia can lead to irreversible damage or death.
  • Inadequate supportive care: Neglecting pain management, nutritional support, or psychological distress can significantly impair patient quality of life and ability to complete treatment.
  • Under-referral to clinical trials: For patients with refractory disease, clinical trials may offer the best chance for novel therapies.
  • Not considering hereditary cancer syndromes: Missing family history patterns that suggest an inherited predisposition can prevent appropriate genetic counseling and risk reduction strategies for family members.

Recent Updates

• Guidelines:
  • Personalized Medicine/Precision Oncology: Increasing emphasis on molecular profiling of tumors to guide treatment selection, moving away from a "one-size-fits-all" approach.
  • Immunotherapy Expansion: Immune checkpoint inhibitors are now standard of care for an expanding list of cancers (e.g., melanoma, lung, renal, bladder, MSI-high colorectal, head & neck) and are moving into earlier disease stages (adjuvant/neoadjuvant).
  • Liquid Biopsy: Growing utility for detecting minimal residual disease, monitoring treatment response, identifying resistance mechanisms, and guiding therapy in real-time, especially for lung and colorectal cancers.
  • Earlier Cancer Screening: Recommendations for colorectal cancer screening initiation for average-risk individuals have been lowered from 50 to 45 years in some guidelines (e.g., ACS, USPSTF).
  • Geriatric Oncology Guidelines: Increasing focus on comprehensive geriatric assessment to tailor treatment for older adults, moving beyond chronological age.
• Evidence:
  • Neo/Adjuvant Immunotherapy: Trials show benefit of immunotherapy in the neoadjuvant (before surgery) and adjuvant (after surgery) settings for cancers like melanoma, lung cancer, and muscle-invasive bladder cancer, reducing recurrence risk.
  • Bispecific Antibodies: Novel agents targeting two different antigens, leading to T-cell mediated killing of cancer cells (e.g., in multiple myeloma, lymphoma).
  • Antibody-Drug Conjugates (ADCs): "Smart chemotherapy" delivering a potent cytotoxic drug directly to cancer cells expressing a specific target antigen (e.g., HER2-low breast cancer, bladder cancer).
  • Radioligand Therapy (RLT): Combining a radioactive isotope with a targeting ligand to deliver radiation directly to cancer cells (e.g., PSMA-targeted RLT for prostate cancer, somatostatin receptor-targeted RLT for neuroendocrine tumors).
  • Improved CAR T-cell Therapy Outcomes: Extended long-term survival for refractory lymphomas and acute lymphoblastic leukemia.
• Controversies:
  • Overdiagnosis and Overtreatment: Particularly for prostate cancer and some thyroid cancers, where screening can detect indolent disease that may never cause harm, leading to unnecessary treatment and side effects.
  • Optimal Duration of Immunotherapy: For many cancers, the optimal duration of immune checkpoint inhibitor therapy is still under investigation, balancing efficacy with long-term toxicity.
  • Role of Artificial Intelligence (AI) in Oncology: While promising for diagnosis (radiomics, pathology image analysis) and treatment prediction, ethical implications, data bias, and regulatory frameworks are still evolving.
  • Health Disparities in Cancer Care: Persistent disparities in incidence, mortality, access to care, and clinical trial participation based on race, ethnicity, socioeconomic status, and geography.

Key References

• Guidelines:
  • National Comprehensive Cancer Network (NCCN) Guidelines: Comprehensive, frequently updated, evidence-based guidelines for diagnosis, staging, and treatment of virtually all cancer types. (Available free for clinicians via NCCN.org registration).
  • European Society for Medical Oncology (ESMO) Clinical Practice Guidelines: Global guidelines for various cancers, often with a European focus.
  • American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines: Evidence-based recommendations for specific clinical questions and cancer types.
  • American Cancer Society (ACS) Guidelines: Focus on screening and prevention recommendations.
  • United States Preventive Services Task Force (USPSTF) Recommendations: Evidence-based recommendations for preventive services, including cancer screening.
• Studies:
  • New England Journal of Medicine (NEJM)
  • Lancet Oncology
  • Journal of Clinical Oncology (JCO)
  • Nature Medicine
  • Cancer Cell
  • Landmark clinical trials for specific cancer types and treatments (e.g., KEYNOTE, CheckMate trials for immunotherapy; FLAIR, PACIFIC trials for lung cancer; JAVELIN, IMbrave for other cancers).
• Reviews:
  • UpToDate (Wolters Kluwer): Comprehensive, evidence-based clinical reference.
  • Harrison's Principles of Internal Medicine - Oncology Section: Classic textbook.
  • DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Comprehensive oncology textbook.
  • PubMed/Medline: For searching and accessing primary literature and review articles.